RhumbLine Advisers’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-16,401
| Closed | -$20K | – | 4184 |
|
|
2025
Q1 | $20K | Sell |
16,401
-1,129
| -6% | -$1.38K | ﹤0.01% | 3738 |
|
|
2024
Q4 | $22.6K | Buy |
17,530
+120
| +0.7% | +$155 | ﹤0.01% | 3788 |
|
|
2024
Q3 | $47.9K | Sell |
17,410
-1,865
| -10% | -$5.13K | ﹤0.01% | 3686 |
|
|
2024
Q2 | $43.6K | Buy |
+19,275
| New | +$43.6K | ﹤0.01% | 3718 |
|
|
2021
Q2 | – | Sell |
-30,689
| Closed | -$67K | – | 3036 |
|
|
2021
Q1 | $67K | Buy |
30,689
+2,425
| +9% | +$5.29K | ﹤0.01% | 2966 |
|
|
2020
Q4 | $63K | Buy |
28,264
+2,830
| +11% | +$6.31K | ﹤0.01% | 3011 |
|
|
2020
Q3 | $68K | Sell |
25,434
-6,365
| -20% | -$17K | ﹤0.01% | 2931 |
|
|
2020
Q2 | $97K | Buy |
31,799
+1,001
| +3% | +$3.05K | ﹤0.01% | 2974 |
|
|
2020
Q1 | $60K | Hold |
30,798
| – | – | ﹤0.01% | 2843 |
|
|
2019
Q4 | $88K | Buy |
30,798
+3,468
| +13% | +$9.91K | ﹤0.01% | 2883 |
|
|
2019
Q3 | $100K | Buy |
27,330
+75
| +0.3% | +$274 | ﹤0.01% | 2885 |
|
|
2019
Q2 | $113K | Buy |
+27,255
| New | +$113K | ﹤0.01% | 2911 |
|
|
2015
Q2 | – | Sell |
-17,755
| Closed | -$59K | – | 3046 |
|
|
2015
Q1 | $59K | Buy |
17,755
+3,400
| +24% | +$11.3K | ﹤0.01% | 2990 |
|
|
2014
Q4 | $50K | Buy |
14,355
+425
| +3% | +$1.48K | ﹤0.01% | 2992 |
|
|
2014
Q3 | $70K | Hold |
13,930
| – | – | ﹤0.01% | 2951 |
|
|
2014
Q2 | $192K | Buy |
+13,930
| New | +$192K | ﹤0.01% | 2853 |
|